Developer docs
API playgroundTry for free, no card

Search company profiles

WILEX

Full company profile

uuid0039d5u

Namestring
WILEX
Websiteurl
wilex.de
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Heidelberg Pharma AG (operating under legacy name WILEX, ticker etr:WL6) is a German clinical-stage biotechnology company headquartered in Ladenburg with a Munich presence, developing oncology therapeutics based on its proprietary ATAC (Antibody Targeted Amanitin Conjugate) platform. The platform combines the targeting specificity of antibodies with Amanitin, a toxin derived from the green death cap mushroom whose RNA polymerase II inhibition mechanism is described as capable of overcoming drug resistance and eliminating quiescent tumor cells — differentiation versus the more common MMAE/DM1-based ADC payloads. The company operates a portfolio that includes its lead candidate HDP-101 (now in Phase II, with recommended dose determined in April 2026) and additional ATAC candidates targeting hematological and solid tumors.

The company's business model is that of a pre-revenue, development-stage biotech: revenue is not yet derived from commercial product sales but is expected to come from out-licensing, milestone payments and royalties once candidates reach market. Currently the model is sustained by capital markets financing (disclosed rounds include Yorkville Advisors in 2010 and a Series 3 round led by Apax Partners/Earlybird/TVM in 2005) and strategic partnerships. A central commercial vehicle is the collaboration with Telix Pharmaceuticals on TLX250-CDx (Zircaix), a kidney cancer imaging agent that has progressed to FDA BLA filing with priority review and a Phase III ZIRCON-CP trial in China. Customer/partner relationships are therefore concentrated around oncology imaging and ADC co-development rather than end-payor revenue.

Customer-facing activity centers on investigator relations, scientific communications (publications, posters, conferences) and investor/stakeholder disclosure (press releases, AGM, financial calendar). Distribution and pricing details are not publicly disclosed given the absence of approved products; commercialization would be expected to leverage established pharmaceutical distribution networks and specialty oncology channels upon any regulatory approval. The company's competitive advantage is grounded in its patented payload chemistry, its specialized conjugation know-how, and its regulatory progress through multiple INDs and clinical milestones.

Short descriptiontext

Heidelberg Pharma (WILEX) is a German clinical-stage biotech developing antibody-drug conjugates based on its proprietary ATAC platform using Amanitin payload for hematological and solid tumor oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLadenburg, Germany
HQ citystring
Ladenburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics, cancer drug development, ADC technology platform, targeted cancer therapy
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development Revenue
TypeLicensing Royalties
Description

Pre-revenue development stage biotech company focused on developing novel cancer therapies using antibody and small molecule platforms. No commercialized products yet; revenue will be generated upon regulatory approval and commercialization of pipeline candidates.

web.archive.org
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

WILEX AG is a Munich-based development-stage biotechnology company developing novel cancer therapies through two complementary platforms — antibody-based therapeutics and small molecule therapeutics — targeting specific patient subpopulations defined by the molecular characterization of their primary tumors. The proprietary ATAC technology combines antibodies with the Amanitin toxin from the green death cap mushroom to create antibody-drug conjugates (ADCs) that can overcome drug resistance and eliminate quiescent tumor cells. The pipeline includes HDP-101 in Phase II for hematological and solid tumors, and out-licensed assets such as TLX250-CDx (kidney cancer imaging) being advanced with Telix Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

WILEX AG is a Munich-based biotech company developing novel cancer therapies through two complementary platforms: antibody-based therapeutics and small molecule therapeutics. The company's approach focuses on treating specific patient subpopulations based on molecular characterization of primary tumors, enabling targeted cancer treatment strategies.

Product and service4 records
1Antibody Platform
CategoryCancer Therapeutics
Description

Antibody-based therapeutic platform developing novel cancer therapies for specific patient subpopulations defined by the molecular characteristics of their primary tumors. Aimed at oncology indications with high unmet need and drug resistance.

2Small Molecule Platform
CategoryCancer Therapeutics
Description

Small molecule-based therapeutic platform developing novel cancer therapies targeting specific patient subpopulations with molecularly characterized tumors, complementary to the Antibody Platform.

3HDP-101
CategoryOncology ADC Drug Candidate
Description

Lead ADC candidate based on the proprietary ATAC platform, being developed for hematological and solid tumors. In Phase II clinical development with recommended Phase II dose determined in April 2026.

4TLX250-CDx (Zircaix) [out-licensed]
CategoryOncology Imaging / Diagnostic
Description

Out-licensed kidney cancer imaging diagnostic developed with partner Telix Pharmaceuticals; BLA filed with FDA and priority review designation granted, with Phase III ZIRCON-CP trial underway in Chinese patients.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Telix Pharmaceuticals is a key strategic partner developing TLX250-CDx (Zircaix) for kidney cancer imaging. The partnership involves FDA BLA filing for TLX250-CDx with priority review granted, Phase III ZIRCON-CP trial in Chinese patients, and ongoing regulatory collaboration. This represents a significant out-licensed product candidate in Wilex/Heidelberg Pharma's pipeline.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Mersana Therapeutics is a clinical-stage biotech developing next-generation ADCs with novel payloads and linkers, making it a relevant emerging peer in the ADC oncology space.

TypeEmerging player
Description

Tubulis is a European biotech developing next-generation ADCs with novel payloads and linkers, making it a directly relevant emerging peer focused on differentiated ADC chemistry.

TypeDirect peer
Description

ADC Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for hematological and solid tumors, making it a directly comparable ADC-focused peer to Heidelberg Pharma.

TypeEmerging player
Description

Molecular Templates develops engineered toxin bodies (ETBs) for oncology, with a similar approach of leveraging novel biological payloads (similar in spirit to Heidelberg Pharma's Amanitin-based ATAC platform).

TypeBroad incumbent
Description

Daiichi Sankyo is a broad incumbent that commercialized Enhertu and datopotamab deruxtecan (with AstraZeneca) using DXd ADC technology — a major competitive force in the ADC market where Heidelberg Pharma operates.

TypeBroad incumbent
Description

AstraZeneca, in partnership with Daiichi Sankyo, is a broad incumbent commercializing Enhertu and a deep ADC pipeline, making it a key competitive force for Heidelberg Pharma's ATAC platform.

TypeEmerging player
Description

Innovent is a China-based biopharmaceutical company with a growing ADC pipeline (including IBI354 and others), representing an emerging peer in the global oncology ADC market.

TypeEmerging player
Description

CytomX develops Probody-drug conjugates — a conditionally activated ADC platform — making it a relevant emerging peer in oncology ADC technology development.

TypeBroad incumbent
Description

Pfizer's acquisition of Seagen in 2023 brought Adcetris, Padcev, and Tivdak into its portfolio, making it a broad incumbent in the ADC space directly relevant to Heidelberg Pharma's competitive landscape.

TypeDirect peer
Description

ImmunoGen pioneered ADC technology and developed Elahere (mirvetuximab soravtansine); acquired by AbbVie in 2024. It is a directly comparable peer in ADC platform development for oncology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WILEX

Biopharmaceutical Oncology Therapeuticswilex.de

Heidelberg Pharma (WILEX) is a German clinical-stage biotech developing antibody-drug conjugates based on its proprietary ATAC platform using Amanitin payload for hematological and solid tumor oncology indications.

What WILEX does

Heidelberg Pharma AG (operating under legacy name WILEX, ticker etr:WL6) is a German clinical-stage biotechnology company headquartered in Ladenburg with a Munich presence, developing oncology therapeutics based on its proprietary ATAC (Antibody Targeted Amanitin Conjugate) platform. The platform combines the targeting specificity of antibodies with Amanitin, a toxin derived from the green death cap mushroom whose RNA polymerase II inhibition mechanism is described as capable of overcoming drug resistance and eliminating quiescent tumor cells — differentiation versus the more common MMAE/DM1-based ADC payloads. The company operates a portfolio that includes its lead candidate HDP-101 (now in Phase II, with recommended dose determined in April 2026) and additional ATAC candidates targeting hematological and solid tumors.

The company's business model is that of a pre-revenue, development-stage biotech: revenue is not yet derived from commercial product sales but is expected to come from out-licensing, milestone payments and royalties once candidates reach market. Currently the model is sustained by capital markets financing (disclosed rounds include Yorkville Advisors in 2010 and a Series 3 round led by Apax Partners/Earlybird/TVM in 2005) and strategic partnerships. A central commercial vehicle is the collaboration with Telix Pharmaceuticals on TLX250-CDx (Zircaix), a kidney cancer imaging agent that has progressed to FDA BLA filing with priority review and a Phase III ZIRCON-CP trial in China. Customer/partner relationships are therefore concentrated around oncology imaging and ADC co-development rather than end-payor revenue.

Customer-facing activity centers on investigator relations, scientific communications (publications, posters, conferences) and investor/stakeholder disclosure (press releases, AGM, financial calendar). Distribution and pricing details are not publicly disclosed given the absence of approved products; commercialization would be expected to leverage established pharmaceutical distribution networks and specialty oncology channels upon any regulatory approval. The company's competitive advantage is grounded in its patented payload chemistry, its specialized conjugation know-how, and its regulatory progress through multiple INDs and clinical milestones.

WILEX firmographics

Firmographics
Name
WILEX
Website
https://wilex.de
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Heidelberg Pharma (WILEX) is a German clinical-stage biotech developing antibody-drug conjugates based on its proprietary ATAC platform using Amanitin payload for hematological and solid tumor oncology indications.
Ownership category
akta.pro rank

WILEX industry classification

Industry
Product category
Biopharmaceutical Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics
  • Cancer drug development
  • ADC technology platform
  • Targeted cancer therapy

Where WILEX is headquartered

Location

Headquarters

HQ city
Ladenburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

WILEX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pipeline Development Revenue: Pre-revenue development stage biotech company focused on developing novel cancer therapies using antibody and small molecule platforms. No commercialized products yet; revenue will be generated upon regulatory approval and commercialization of pipeline candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

WILEX product offering

Product offering

Core offering

WILEX AG is a Munich-based development-stage biotechnology company developing novel cancer therapies through two complementary platforms — antibody-based therapeutics and small molecule therapeutics — targeting specific patient subpopulations defined by the molecular characterization of their primary tumors. The proprietary ATAC technology combines antibodies with the Amanitin toxin from the green death cap mushroom to create antibody-drug conjugates (ADCs) that can overcome drug resistance and eliminate quiescent tumor cells. The pipeline includes HDP-101 in Phase II for hematological and solid tumors, and out-licensed assets such as TLX250-CDx (kidney cancer imaging) being advanced with Telix Pharmaceuticals.

Product overview

WILEX AG is a Munich-based biotech company developing novel cancer therapies through two complementary platforms: antibody-based therapeutics and small molecule therapeutics. The company's approach focuses on treating specific patient subpopulations based on molecular characterization of primary tumors, enabling targeted cancer treatment strategies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibody Platform Antibody-based therapeutic platform developing novel cancer therapies for specific patient subpopulations defined by the molecular characteristics of their primary tumors. Aimed at oncology indications with high unmet need and drug resistance.
  • Small Molecule Platform Small molecule-based therapeutic platform developing novel cancer therapies targeting specific patient subpopulations with molecularly characterized tumors, complementary to the Antibody Platform.
  • HDP-101 Lead ADC candidate based on the proprietary ATAC platform, being developed for hematological and solid tumors. In Phase II clinical development with recommended Phase II dose determined in April 2026.
  • TLX250-CDx (Zircaix) [out-licensed] Out-licensed kidney cancer imaging diagnostic developed with partner Telix Pharmaceuticals; BLA filed with FDA and priority review designation granted, with Phase III ZIRCON-CP trial underway in Chinese patients.

Companies that use WILEX

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

WILEX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

WILEX partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Telix PharmaceuticalscoreStrategic or Co-development Partner · 26 February 2025Telix Pharmaceuticals is a key strategic partner developing TLX250-CDx (Zircaix) for kidney cancer imaging. The partnership involves FDA BLA filing for TLX250-CDx with priority review granted, Phase III ZIRCON-CP trial in Chinese patients, and ongoing regulatory collaboration. This represents a significant out-licensed product candidate in Wilex/Heidelberg Pharma's pipeline.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

WILEX competitors and assessment

Company assessment

Emerging players

  • Mersana Therapeutics: Mersana Therapeutics is a clinical-stage biotech developing next-generation ADCs with novel payloads and linkers, making it a relevant emerging peer in the ADC oncology space.
  • Tubulis: Tubulis is a European biotech developing next-generation ADCs with novel payloads and linkers, making it a directly relevant emerging peer focused on differentiated ADC chemistry.
  • Molecular Templates: Molecular Templates develops engineered toxin bodies (ETBs) for oncology, with a similar approach of leveraging novel biological payloads (similar in spirit to Heidelberg Pharma's Amanitin-based ATAC platform).
  • Innovent Biologics: Innovent is a China-based biopharmaceutical company with a growing ADC pipeline (including IBI354 and others), representing an emerging peer in the global oncology ADC market.
  • CytomX Therapeutics: CytomX develops Probody-drug conjugates — a conditionally activated ADC platform — making it a relevant emerging peer in oncology ADC technology development.

Direct peers

  • ADC Therapeutics: ADC Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for hematological and solid tumors, making it a directly comparable ADC-focused peer to Heidelberg Pharma.
  • ImmunoGen (now part of AbbVie): ImmunoGen pioneered ADC technology and developed Elahere (mirvetuximab soravtansine); acquired by AbbVie in 2024. It is a directly comparable peer in ADC platform development for oncology.

Broad incumbents

  • Daiichi Sankyo: Daiichi Sankyo is a broad incumbent that commercialized Enhertu and datopotamab deruxtecan (with AstraZeneca) using DXd ADC technology — a major competitive force in the ADC market where Heidelberg Pharma operates.
  • AstraZeneca: AstraZeneca, in partnership with Daiichi Sankyo, is a broad incumbent commercializing Enhertu and a deep ADC pipeline, making it a key competitive force for Heidelberg Pharma's ATAC platform.
  • Pfizer (Seagen): Pfizer's acquisition of Seagen in 2023 brought Adcetris, Padcev, and Tivdak into its portfolio, making it a broad incumbent in the ADC space directly relevant to Heidelberg Pharma's competitive landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

WILEX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WILEX leadership team

Management profile

Number of profiles

WILEX funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WILEX M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WILEX

What does WILEX do?

WILEX AG is a Munich-based development-stage biotechnology company developing novel cancer therapies through two complementary platforms — antibody-based therapeutics and small molecule therapeutics — targeting specific patient subpopulations defined by the molecular characterization of their primary tumors. The proprietary ATAC technology combines antibodies with the Amanitin toxin from the green death cap mushroom to create antibody-drug conjugates (ADCs) that can overcome drug resistance and eliminate quiescent tumor cells. The pipeline includes HDP-101 in Phase II for hematological and solid tumors, and out-licensed assets such as TLX250-CDx (kidney cancer imaging) being advanced with Telix Pharmaceuticals.

Is WILEX a public or private company?

WILEX is a private company. It is classified as public and is currently operating.

When was WILEX founded?

WILEX was founded in 1997. It employs 11 to 50 people.

Where is WILEX based?

WILEX is headquartered in Ladenburg, Germany, in the Europe region.

How does WILEX make money?

One revenue line is on record: pipeline Development Revenue.

Who are WILEX's main competitors?

Emerging players on record are Mersana Therapeutics, Tubulis, Molecular Templates, Innovent Biologics and CytomX Therapeutics. Direct peers are ADC Therapeutics and ImmunoGen (now part of AbbVie). Broad incumbents are Daiichi Sankyo, AstraZeneca and Pfizer (Seagen).

Does WILEX have an API?

No public API is recorded for WILEX.

What industry is WILEX in?

WILEX's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deHeidelberg Pharma drückt den Verlust deutlich, doch wie lange reicht das Geld?Heidelberg Pharma reported a loss of 8.7 million euros for the first nine months of 2026, down from 21.1 million euros. The company is developing antibody-drug conjugates using amanitin, a toxin from the death cap mushroom.FinanzNachrichten.deEQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über die ersten neun Monate des Geschäftsjahres 2026Heidelberg Pharma reported its first nine months of fiscal 2026, with revenue and earnings up 79% year-over-year and cost-cutting savings of about 30%. The company's lead ADC HDP-101 reached a recommended Phase 2 dose of 175 µg/kg, and it received NMPA approval for a combination study in China.The future of tradingHeidelberg Pharma Names Peter Willinger CFO, Replacing Walter MillerPeter Willinger succeeded Walter Miller as Heidelberg Pharma's chief financial officer, effective May 1, 2026. Miller left at his own request when his contract expired at the end of April 2026.FinanzNachrichten.deEQS-News: Heidelberg Pharma AG: Heidelberg Pharma präsentiert neue klinische Daten zum führenden ATAC-Kandidaten pamlectabart tismanitin auf der IMS-Jahrestagung 2026Heidelberg Pharma presented Phase I/IIa data for its BCMA-ATAC candidate pamlectabart tismanitin at the IMS 2026 conference. The recommended Phase 2 dose was set at 175 µg/kg, with a 42% overall response rate in 53 patients. The company plans to proceed to Phase IIa.The future of tradingHeidelberg Pharma sets 175 µg/kg RP2D for pamlectabart tismanitin in Phase I/IIa multiple myeloma trialHeidelberg Pharma presented Phase I/IIa data on pamlectabart tismanitin at the IMS Annual Meeting 2026, supporting a Phase 2 dose selection. The trial showed favorable safety with no dose-limiting ceiling in heavily pretreated relapsed or refractory multiple myeloma patients. A Phase IIa expansion is ongoing with enrollment progressing as planned.European BiotechnologySimris steps on Heidelberg Pharma’s toes with amanitin pivotSimris Group is pivoting to amanitin-based antibody-drug conjugates under former Heidelberg Pharma CEO Andreas Pahl, who joined Simris Bilogics in July. Heidelberg Pharma has expressed interest in licensing its proprietary amanitin technology, but no agreement has been announced. Simris plans to recruit six ADC specialists and take two programs toward the clinic within 18 months.European BiotechnologyHeidelberg Pharma deepens ADC alliance with HuadongHeidelberg Pharma and China's Huadong Medicine are expanding their partnership to jointly research and develop ADCs against up to six targets, including bispecific and multispecific candidates. The 2022 deal gave Huadong exclusive Asian rights to HDP-101 and HDP-103, a $20 million upfront payment, up to $449 million in milestones and tiered royalties, plus a ~35% stake.FinanzNachrichten.deEQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma und Huadong Medicine unterzeichnen weitere Kooperationsvereinbarung zur gemeinsamen Entwicklung neuer Antikörper-Wirkstoff-KonjugateHeidelberg Pharma AG announced on 28 August 2026 that its wholly-owned Heidelberg Pharma Research GmbH signed a further cooperation agreement with strategic partner Huadong Medicine Co., Ltd. of Hangzhou, China, to jointly research and develop new antibody-drug conjugates. The deal deepens collaboration in research and early development, combining Heidelberg's proprietary ATAC toxin platform with Huadong's capabilities, targeting up to six target molecules. Financial terms were not disclosed.FinanzNachrichten.deEQS-News: Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in ChinaHeidelberg Pharma AG announced on 26 August 2026 that China's National Medical Products Administration approved a Phase Ib/II clinical study of its BCMA-targeted ADC pamlectabart tismanitin (HDP-101) in combination with pomalidomide/dexamethasone or daratumumab/dexamethasone for relapsed/refractory multiple myeloma. Huadong Medicine, which bears development costs, will conduct the study in China.Startuprad.io Startup PodcastThis Month in DACH Startups - October 2025 | Deep DiveThe October 2025 DACH startup ecosystem roundup documents continued investment momentum in climate tech, deep tech, and AI infrastructure across Germany, Austria, and Switzerland, with notable deals including Energy Vault's $300 million raise and multiple mid-stage financings in robotics, compliance, and agritech. Key ecosystem shifts include leadership changes at Aleph Alpha, potential BioNTech acquisition of CureVac, and Scalable Capital obtaining a banking license, alongside layoffs at Fernride and Heidelberg Pharma reflecting ongoing unit-economic pressures. The report signals investor preference for capital-intensive ventures with defensible technology moats as Europe's startup ecosystem adapts to tighter late-stage funding conditions.